updated 2/28/2011 1:16:01 PM ET 2011-02-28T18:16:01

CAMBRIDGE, Mass., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today its alliance with the National Organization for Rare Disorders (NORD) and observance of the fourth annual Rare Disease Day. NORD is coordinating this observance with the support of more than 200 patient organizations, professional societies, government agencies, medical researchers and pharmaceutical and biotechnology companies to raise awareness about rare diseases.

Aegerion is currently in late-stage clinical development for an orphan drug candidate, lomitapide, a small molecule, once-a-day, oral therapy to treat homozygous familial hypercholesterolemia (HoFH). HoFH is a rare genetic lipid disorder resulting in an accumulation of low-density lipoprotein (LDL-C), often referred to as bad cholesterol, in the blood. Patients with HoFH are at severely high risk of experiencing a heart attack or stroke in their twenties, and if untreated, patients with HoFH generally die before the age of thirty.

A rare disease is one that affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was first observed in Europe in 2008. It was established by EURORDIS, the European Rare Disease Organization. In 2009, EURORDIS partnered with NORD for this initiative in the United States. For more information about Rare Disease Day, visit www.rarediseases.org .

Marc D. Beer, CEO of Aegerion, commented, "We share NORD's interest in creating awareness about rare diseases and calling attention to the frequent lack of effective diagnosis and treatment for these underserved patients. It is our ongoing mission to advance research and development and improve care for patients with rare disorders."

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Corporate
         Will Lewis, President
         +1 (908) 704-1300
         
         LaVoie Group, Inc.
         Investors & Media
         Amanda Murphy
         +1 (978) 745-4200 x107
         amurphy@lavoiegroup.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com